– Phase 2 Study of Duvelisib with Background Methotrexate in Patients with Moderate-to-Severe Rheumatoid Arthritis Did Not Meet Primary Endpoint – – Infinity to Continue Focusing Its Efforts on the ...
Infinity Pharma INFI announced additional details on the design of its phase II MARIO-8 study, evaluating eganelisib for squamous cell cancer of the head and neck (SCCHN). Shares of the company were ...
Shares of Infinity Pharmaceuticals Inc.INFI rose almost 24% after the company announced that it has entered into a master clinical supply agreement with Roche RHHBY. Per the deal, Roche will supply ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”), a clinical-stage biotechnology company developing eganelisib, a ...
-- Company to Host Conference Call Today at 8:30 a.m. ET -- Infinity Pharmaceuticals, Inc. INFI -50.75% today announced interim data from its double-blind, randomized, placebo-controlled Phase 2 study ...
LONDON--(BUSINESS WIRE)--Infiniti Research, a global competitive intelligence solutions provider, has announced the release of their latest market entry study on the packaging industry. The client, a ...
DALLAS — Both the Summit Apex Plus excimer laser and its successor, the Infinity LS system, effectively treat hyperopic astigmatism, according to the results of a multicenter study. “Unlike the Visx ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced interim data from its double-blind, randomized, placebo-controlled Phase 2 study comparing saridegib ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback